Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Chief Financial Officer Greg Guyer - Chief Technical Officer, Manufacturing and Technical Operations Conference Call Participants Salveen Richter - Goldman Sachs Geof ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-26727 ______________________________________ BioMarin Pharmaceutical Inc ...

Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ Form 10-Q Commission File Number: 000-26727 ______________________________________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) ______________________________________ Delaware 68-0397820 (State or other jurisdiction of incorpo ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q2 2023 Earnings Conference Call July 31, 2023 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Chief Financial Officer Greg Guyer - Chief Technical Officer, Manufacturing and Technical Operations Conference Call Participants Akash Tewari - Jefferies Salveen Richte ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------------|---------------------------------------------------------------------------------------|-------|---------------------------------------------|-------|--------| | Assets: | Significant | Fair Value Measurements as of December 31, 2022 \n Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) | | Total | | Other current assets: | | | | | | | | NQDC Plan assets | $ | 2,654 | $ | — | $ | 2,654 ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET Company Participants Traci McCarty - Group VP, IR Jean-Jacques Bienaime - Chairman & CEO Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - CFO & EVP Conference Call Participants Salveen Richter - Goldman Sachs Group Geoffrey Meacham - Bank of America Merrill Lynch Christopher Raymond - Piper Sandler & Co. Timothy Lugo - William Blair & Company ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Traci McCarty - Group VP, IR JJ Bienaimé - Chairman and CEO Jeff Ajer - EVP and Chief Commercial Officer Hank Fuchs - President, Worldwide R&D Greg Guyer - EVP and Chief Technical Officer Brian Mueller - EVP and CFO Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen and Company Jessica Fye - JPMorgan Chase Chris Raymond - P ...

We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations. • trade protection measures and import or export licensing requirements; • changes in international medical reimbursement policies and programs; Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russia's invasion of Ukraine a ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP & Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - EVP, Finance & CFO Conference Call Participants Philip Nadeau - Cowen and Company Salveen Richter - Goldman Sachs Jessica Fye - JPMorgan Chase & Co. Srikripa Devarakonda - Truist Securities Paul Matteis - Stifel, ...